Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation. The method, called “Perturb-multiome,” uses CRISPR to knock out the function of individual transcription factors across many blood cells at once. The researchers then perform single-cell analyses on each cell to measure the effects of the editing, including identifying which genes have been turned on or off and which genes are accessible (based on epigenetic markers). 

Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic “marks” in a transition state between normal and pancreatic cancer cells in mice, and that the normal cells may keep at least a temporary “memory” of those cancer-linked marks. 

BUFFALO, NY – April 4, 2025 – A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT.”

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an assessment of cancer stem cell sensitivity to chemotherapy can accurately decide more effective treatments and lead to increased outcomes for patients with platinum-resistant ovarian cancer. 

BUFFALO, NY — April 4, 2025— A new case report was published in Oncoscience’s Volume 12 on March 31, 2025, titled “Cystadenofibroma and contralateral collision lesions: A unique ovarian case report.”